canceraustralia.gov.au€¦ · web viewinvitation to apply for funding . support for cancer...

Invitation to Apply for Funding Support for Cancer Clinical Trials Program2013-16 Funding Round for the National Cancer Cooperative Trials Groups

Instructions for Submitting Applications for Funding

Applications close at 5.00pm Australian Eastern Standard Time on Monday 6 May 2013 (Closing Time).

You must submit your Application by email to: [email protected]

The email should quote Support for Cancer Clinical Trials in the subject heading.

Applications should be submitted as one signed copy in PDF format (Filename: Support for Cancer Clinical Trials _Applicants Name) and one MS Office Word format (do not exceed 5MB in size).

Applicants may confirm safe receipt of submitted quotes by telephoning the Contact Officer, Gayle Jones, on 03 8866 0448.

Applications must be emailed to allow sufficient time for them to be received before the closing time. Applicants should be aware that there can be delays and uncertainties in the delivery of email, and it is the responsibility of the person or organisation making the submission to make sufficient time allowance for their submission to be received before the closing time.

Cancer Australia is under no obligation to provide suppliers with confirmation of delivery of applications.

Answers to questions must be no more than one page in length, unless otherwise specified on the application form.

Applicants should refrain from using acronyms in the application form.

Late Applications

Cancer Australia will only accept your Application, if it is late, as a direct result of mishandling by Cancer Australia. In all other circumstances, in the interests of fairness, Cancer Australia reserves the right not to accept late Applications. In considering whether it would be fair to accept a late Application, Cancer Australia will take into account the degree of lateness, whether the cause of the lateness was beyond the Applicant's control and such other facts as it considers relevant. Cancer Australia may also ask the Applicant to provide evidence to support its claims regarding the reasons for late submittal. If the Applicant considers that their Application will be late they should notify the Contact Officer prior to the Closing Time, advising of the circumstances for the lateness. The Chair of the assessment committee will take these reasons into consideration when deciding whether or not to accept the late Application.

ITA 1213-02 of 34

mailto:[email protected]

Contact Officer

All enquiries relating to this Invitation to Apply for Funding should be directed in writing to the Contact Officer, Gayle Jones, at [email protected]

Structure of this Invitation to ApplyPart A General information for Applicants

Part B Assessment of applications

Part C How to apply for funding

Part D Application form

Part E Frequently asked questions

ITA 1213-02 of 34

mailto:[email protected]

Part A - General information for Applicants

1 Background The Australian Government through its Agency, Cancer Australia, is seeking funding applications from the 13 National Cancer Cooperative Trials Groups currently funded under the Support for Cancer Clinical Trials program. Cancer Australia will provide direct funding to each National Cancer Cooperative Trials Group of up to $460,000 GST exclusive ($506,000 GST inclusive) per financial year, up to a maximum of $1,380,000 million GST exclusive ($1,518,000 GST inclusive) over a maximum three years. Cancer Australia will also provide access to National Technical Services of up to $75,000 per annum per Group. The funding will be provided to support the development of industry-independent cancer clinical trials protocols over a period of up to three years from 1 July 2013 to 30 June 2016.

2 Policy contextClinical trials benefit the community by improving the survival of people affected by cancer, and contribute to a reduction in premature death and disability. Clinical trials are fundamental to establishing whether new cancer treatments, diagnostic tests or preventive interventions are effective and they help generate evidence for best-practice cancer care.The funding is being provided as part of the Support for Cancer Clinical Trials Program to support Australia’s 13 National Cancer Cooperative Trials Groups develop industry-independent cancer clinical trials to guide scientific improvements in cancer prevention, treatment and care and in doing so build the evidence-base for best practice cancer care to improve health outcomes for Australian’s affected by cancer. You can find more information about the Program on the Cancer Australia website: http://canceraustralia.gov.au/research-data/support-clinical-trials

3 Funding objectivesThe funding is being provided to support the development of industry-independent cancer clinical trials and in doing so:a) Increase the participation in clinical trials by people affected by

cancerb) Increase the number of cancer clinical trials conducted in Australiac) Increase the number of clinical sites actively participating in

clinical trials

ITA 1213-02 of 34

http://canceraustralia.gov.au/research-data/support-clinical-trials

d) Increase the professional capacity to conduct clinical trials within Australia

4 What will be funded?The Agency expects that the funding will be awarded for staffing, administrative, and minor assets costs (up to $5,000 (GST exclusive)) that support existing National Cancer Cooperative Trials Groups to develop industry-independent cancer clinical trials protocols to the stage of applying for grant funding. Funding will be considered for activities such as those listed in the Table below:

Salaries for Scientific, Clinical and/ or Administrative personnel to support trials design and protocol development to the stage of submission of a grant application

Activities include: Literature reviews Peer review and approval of concept Protocol development including:

o Identification of sponsoro Identification of potential sites

for patient recruitmento Statistical evaluation of

concept including: Sample size and other

relevant statistical calculation

Design of data fields Design of CRF Data management

evaluation processo Financial Evaluation and

budget preparation writing protocols, writing grant applications

Education and training in clinical trials design

Funding support for: training within Australia, of National

Cancer Cooperative Trials Groups members in clinical trials design and management

Such funding support would include attendance at workshops offered by groups like ACCORD and can include associated travel costs to attend training within Australia

Office costs Funding support for: office costs i.e. premises rental,

stationeryIT support and communications

Funding support for: hardware (i.e. computers,

telephones) and software telephone line rental and

teleconference costs for COGs business and meetings

website hosting and maintenance/ upgrade

ITA 1213-02 of 34

Travel Funding support for: Face-to-face COGs group meetings

for trials development Group committee meetings - Includes

venue, catering, and accommodation costs

International travel for trials protocol development

International travel must be approved prior to the meeting by the Cancer Australia CEO, economy class airfares (max of 3 international fares per annum)

5 What will not be funded?The Agency will not provide funds for the following:

Activities associated with the conduct of specific cancer clinical trials. It is expected that competitive grant funding will be applied for to support conduct and management of specific cancer clinical trials and associated activities such as site activation, ethics applications, and quality assurance activities.

Overseas sites, international members or the conduct of specific cancer clinical trials outside Australia.

The support of health professionals from other countries. Clinical service delivery or infrastructure for clinical services. The management of this grant/ Funding Agreement, in particular:

o bank fees;o legal costs;o University overheads;o time taken to manage the Funding Agreement/ prepare

progress/ final reports for Cancer Australia in relation to the grant/ Funding Agreement; and

o indemnity and insurance costs The development or printing of corporate sponsorship material. Fundraising activities or staff salaries to support fundraising

activities. Assets over $5,000 (GST exclusive).

ITA 1213-02 of 34

6 Who can apply for the funding?6.1 The following Groups are eligible to apply for funding:

Australasian Gastro-Intestinal Trials Group; Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australasian Sarcoma Study Group; Australia and New Zealand Melanoma Trials Group; Australia New Zealand Gynaecological Oncology Group; Australian and New Zealand Children’s Haematology and

Oncology Group; Australian and New Zealand Urogenital and Prostate Cancer

Trials Group; Australian New Zealand Breast Cancer Trials Group; Cooperative Trials Group for Neuro-Oncology; Psycho-Oncology Co-operative Research Group; Trans-Tasman Radiation Oncology Group; and Primary Care Collaborative Cancer Clinical Trials Group

For legal and accountability reasons, only incorporated bodies can enter into a Funding Agreement with the Australian Government. It is not necessary for the National Cancer Cooperative Trials Group to become a company limited by guarantee nor a separately incorporated body. The Group can administer its Funding Agreement through an incorporated body who can receive funding payments from Cancer Australia and make these available to the National Cancer Cooperative Trials Group.

7 How much funding is available?7.1 Cancer Australia reserves the right to negotiate the level of funding

and the timeframe of funding with each Applicant. Each National Cancer Cooperative Trials Group may apply for direct funding of up to $460,000 GST exclusive ($506,000 GST inclusive) per annum of funding which will be distributed to the successful Applicants for activities during 1 July 2013 to 30 June 2016. Cancer Australia anticipates that the first payment of funding to the successful Applicants will occur on execution of the Funding Agreement and by 1 July 2013.

7.2 The maximum grant is up to $1,380,000 million GST exclusive ($1,518,000 GST inclusive) over a maximum three years. (NB – if an individual is not registered for GST, or an organisation is a Government-Related Entity, value will be GST exclusive).

ITA 1213-02 of 34

8 Timeframes8.1 Cancer Australia anticipates that it will select the successful funding

Applicants by 24 May 2013 and Letters of Offer and Funding Agreements will be sent to successful Applicants by 31 May 2013.

8.2 Cancer Australia may not notify unsuccessful Applicants until it has executed Funding Agreements with the successful Applicants.

9 Funding agreement9.1 The successful Applicants for funding will be required to sign a

Funding Agreement with the Commonwealth, represented by Cancer Australia, before receiving any funding.

9.2 The Schedule attached to the Funding Agreement will provide a detailed description of the project based on the Application. The funding may be paid in instalments throughout the project. The payment of funding is generally based on the funding recipient's achievement of outcomes and provision of deliverables (such as progress reports) and the demonstration of need for the instalment.

9.3 Applicants should note that, if they are successful, some details of their project (including a project outline, their name and the amount of funding awarded) will be posted on the Agency’s website as part of Cancer Australia’s legislative reporting obligations.

10 Insurance All Applicants should ensure that they have in place, or if successful are able to obtain, sufficient insurance to comply with the requirements for insurance specified below. Workers Compensation to an amount required by law, $10,000,000 Public Liability, and $20,000,000 Professional Indemnity.

10.1 A Funding Agreement with a short listed Applicant will not be executed until the required insurances have been obtained and copies of certificates of currency for the required insurances provided to the Agency.

ITA 1213-02 of 34

Part B - Assessment of Applications

1 How will the Applications for funding be assessed?1.1 An assessment committee will be established by Cancer Australia to

assess Applications against the assessment criteria and select the successful Applicants. The assessment committee will consist of officers from Cancer Australia, representatives with expertise in funding cancer clinical trials and community representatives. The assessment committee will make recommendations to Cancer Australia’s Funding Approver regarding the applications to be supported and the recommended levels of funding.

1.2 The Contact Officer will undertake an initial screening of Applications received against Part D, Section 1 to ensure Applicants meet the minimum requirements such as Legal Entity, required insurance levels or willingness to obtain, and completion of Sections 3 and 4.

2 Assessment criteria2.1 When assessing the Applications for funding, the assessment

committee will use the assessment criteria in Part D, Section 2.2.2 The assessment criteria are not listed in any particular order and all

assessment criteria will be equally weighted. 2.3 In assessing an Application against the assessment criteria, the

assessment committee may consider the Applicant's financial viability and the risk of the Application.

2.4 In assessing an Application, the committee may use material included in response to one assessment criterion in the assessment of other criteria.

2.5 The assessment committee may also seek information about any Applicant from any other source, including from within the Commonwealth, whether or not the individuals or organisations contacted are nominated as referees by the Applicant.

ITA 1213-02 of 34

Part C - How to apply for funding

1 Complete the Application form1.1 You must submit your Application for funding on the Application form

in Part D. 1.2 The Declaration in the Application form must be signed by a person

authorised to act on behalf of the National Cancer Cooperative Trials Group and the incorporated body through which the grant will be administered.

1.3 The Application form must be completed in English. 1.4 If you are from a non-government or private sector organisation, you

must include in your Application: 1.4.1 one (1) copy of the organisation's Certificate of

Incorporation; and 1.4.2 one (1) copy of the organisation's previous financial year's

audited financial statements. Cancer Australia may ask for further information about the Applicant's financial viability.

1.5 If the National Cancer Cooperative Trials Groups is administering its Funding Agreement through an incorporated body which is a University, then Clause 1.4 does not apply.

ITA 1213-02 of 34

2 Complete the Application checklist2.1 Before you submit your Application, complete the following

checklist to ensure that your Application is complete. Before you begin

[ ] Read the Grant Guidelines

[ ] Read this Invitation to Apply for Funding (including Part E (Frequently Asked Questions))

[ ] Ensure that you understand the assessment criteria for the Program set out in Part D, Section 2 (Funding Request).

[ ] Read Cancer Australia’s Funding Agreement, available to be downloaded with this Invitation to Apply for Funding. When you submit an Application, you must confirm that, if your Application is successful, you will accept the terms of the Funding Agreement.

[ ] Read the Supporting Cancer Clinical Trials in Australia Principles Document, Supporting Cancer Clinical trials in Australia Evaluation Framework and Performance Criteria and the Support for Cancer Clinical Trials - Guide to travel/ meeting policy for National Cancer Cooperative Trials Groups document.

Completing your Application

[ ] Use the template Application Form in Part D and complete every Section.

[ ] Complete the Application Form in English and restrict your responses to a maximum of one page in length, unless otherwise specified.

[ ] Indicate that the Applicant makes the acknowledgements in Part D, Section 3 of the Application Form, by selecting 'YES'.

[ ] Complete and sign the Declaration in Part D, Section 4 of the Application Form (Note: The Declaration must be signed by an authorised officer of the Applicant).

Submitting your Application

[ ] Check that you have completed each Section of the Application Form.

[ ] Check that the Application form has been signed.

ITA 1213-02 of 34

[ ] Check that you have prepared and attached all relevant supporting documentation.

For non-government Applicants:

[ ] Attach to the Application one (1) copy of the Applicant's Certificate of Incorporation. (Not applicable if the National Cancer Cooperative Trials Groups is administering its Funding Agreement through an incorporated body which is a University)

[ ] Attach to the Application one (1) copy of the Applicant's previous financial year's audited financial statements. (Not applicable if the National Cancer Cooperative Trials Groups is administering its Funding Agreement through an incorporated body which is a University)

3 Submit your Application3.1 You must submit your Application for funding in accordance with

the submission details and methods on the cover page of the Invitation to Apply for Funding.

3.2 You are responsible for ensuring that your Application is completed accurately.

3.3 You may not alter the substance of your Application following its submission, except if you discover an error in your Application you should inform the Contact Officer immediately in writing. Cancer Australia may seek information from you to clarify any aspect of your Application, but it is not required to do so.

3.4 Prior to the closure of the Invitation to Apply for Funding, if the Applicant discovers an error in their submission, you should inform the contact officer immediately in writing.

3.5 Cancer Australia reserves the right to reject incomplete or faxed applications.

4 Retain a copy of your Application4.1 It is suggested that you retain a copy of your Application for your

records.

ITA 1213-02 of 34

Part D - Application form

Please submit your Application in the following form.

Section 1 - Applicant Details

Details of ApplicantDetail required Applicant's response:

National Cancer Cooperative Trials Group Name

Registered Business Name of incorporated body through which the Funding Agreement will be administered

[This must be the name of the legal entity through which the Funding Agreement will be administered if the Application for funding is successful]

Australian Business Number (ABN)

[If the incorporated body is an entity registered on the Australian Business Register, then the ABN must be provided]

Australian Company Number (ACN)

[If the incorporated body is an Australian company then the ACN must be provided unless the number also appears in the ABN given above]

Registered Business Address

[This needs to be the official address in respect of the legal entity submitting the Application]

ITA 1213-02 of 34

Detail required Applicant's response:

Address for Notices

[This needs to be the address the Applicant primarily wishes to be used for notices given under any contract (if different to the Registered Business Address)]

Insurance

Confirm current insurance levels are consistent with Part A, Clause 10

OR

Confirm willingness to obtain required levels of insurance if successful.

Authorised contacts

Preferred Contact Alternative Contact

Name:

Position/Title:

Postal Address:

Street Address:

Phone Number:

Fax Number:

Email:

ITA 1213-02 of 34

Section 2 - Funding request

Assessment criterion 1 – Compliance with principles

In 2007, the Supporting Cancer Clinical Trials in Australia Principles Document was developed by Cancer Australia in consultation with the National Cancer Cooperative Trials Groups and Cancer Australia’s Research Advisory Group. The principles form a guiding framework for the National Cancer Cooperative Trials Groups as they apply for funding from the Support for Cancer Clinical Trials program. It is a condition of continued funding that the National Cancer Cooperative Trials Groups continue to demonstrate compliance with these guiding principles.National principles

For the period 1 July 2013 to 30 June 2016, please describe the National Cancer Cooperative Trials Group’s proposed activities against the following national principles:

Principle 1 – National multidisciplinary membership

Please describe how the National Cancer Cooperative Trials Group will continue to increase its membership across disciplines, states and territories and regional locations. (limit 200 words)

Response:

ITA 1213-02 of 34

Principle 2 & 3 – Governance structure and succession planning

Please describe any intended changes to governance structure of the National Cancer Cooperative Trials Group and identify the process of succession planning to be developed or implemented. (limit 200 words)

Response:

Principle 4 – Strategic and business planning

Please describe planned strategic and business planning activities. (limit 200 words)

Response:

ITA 1213-02 of 34

Principle 5 – Data and quality

Please describe what activities the National Cancer Cooperative Trials Group will undertake to review procedures and data systems to ensure conduct of clinical trials is of the highest quality. (limit 200 words)

Response:

Principle 6 Capacity building

Please describe how the National Cancer Cooperative Trials Group will increase the number of cancer clinical trials undertaken and increase the Group’s capacity to undertake cancer clinical trials. In responding to this question, please comment on strategies to increase the number of collaborating hospitals/ centres and strategies to identify/ leverage funding. (limit 200 words)

Response:

Principle 7 – Increasing participation in clinical trials

ITA 1213-02 of 34

Please describe how the National Cancer Cooperative Trials Group will increase participation of people with cancer in clinical trials. In responding to this question please comment on how the Group will increase trial participation in groups/ areas where there is currently low clinical trials participation. (limit 200 words)

Response:

Principle 8 – Collaboration and mentoring

Please describe how the National Cancer Cooperative Trials Group will collaborate and provide ongoing peer support to other National Cancer Cooperative Trials Groups. (limit 200 words)

Response:

Principle 9 – Translation into policy and practice

ITA 1213-02 of 34

Please describe how the National Cancer Cooperative Trials Group will optimise the update of clinical trials findings into practice, policy or further research. (limit 200 words)

Response:

ITA 1213-02 of 34

Assessment criterion 2 – How the renewed funding will be utilised

Key Activities and TimeframesFor each of three financial years, please specify the key activities the National Cancer Cooperative Trials Group will undertake in the following areas?

Key activities Outcome of key activity

2013-14

Clinical trials design and protocol development

e.g. to support the review and discussion of new clinical trials concepts at ASM

1.

2.

3.

4..

(add more rows if required)

e.g. a minimum of 3 new clinical trials concepts accepted for protocol development following the ASM

1.

2.

3.

4.


ITA 1213-02 of 34



e.g. to support the development of clinical trials protocols by young clinicians/ researchers

1.

2.

3.

4.


e.g. up to 3 clinicians/researchers attend ACCORD workshop

1.

2.

3.

4.


Communication e.g. to update the National Cancer Cooperative Trials Group website to have a secure members only page

1.

2.

3.

4.


e.g. a secure members only page developed to support confidential peer review of clinical trials concepts

1.

2.

3.

4.


ITA 1213-02 of 34


National Cancer Cooperative Trials Group/ committee meetings

e.g. quarterly meetings of the scientific advisory committee

1.

2.

3.

4.


e.g. up to 10 new clinical trial proposals approved for development annually

1.

2.

3.

4.


2014-15



1.

2.

3.

4.



1.

2.

3.

4.


ITA 1213-02 of 34


Education and training in clinical trial design


1.

2.

3.

4.



1.

2.

3.

4.



1.

2.

3.

4.


e.g. a secure members only page developed to support confidential peer review of clinical trials concepts

1.

2.

3.

4.


ITA 1213-02 of 34




1.

2.

3.

4.



1.

2.

3.

4.


2015-16



1.

2.

3.

4.



1.

2.

3.

4.


ITA 1213-02 of 34




1.

2.

3.

4.



1.

2.

3.

4.



1.

2.

3.

4.


e.g. A secure members only page developed to support confidential peer review of clinical trials concepts

1.

2.

3.

4.


ITA 1213-02 of 34




1.

2.

3.

4.



1.

2.

3.

4.


ITA 1213-02 of 34

Assessment criterion 3 – Budget and Value for Money Guidance for completing the Budget

Staffing costs: Provide a separate line item for each person to be employed. Include their title, Name, FTE, award rate (if applicable) and all on-costs (workers' compensation, superannuation, leave).

Administrative costs: Provide a separate line item for each of the following (if applicable) (a)education and training; (b) office costs; (c) IT support; (d) travel.

Asset costs: Provide a separate line item for small office assets <$5000 (GST exclusive) (if any) such as mobile phones or laptop computers required to undertake the project.

Total Group Costs sought: Indicate the total funding sought by the National Cancer Cooperative Trials Group in this Application for Staffing, Administrative costs and Asset costs and GST (if applicable)).

Goods and Services Tax (GST): Identify the amount of GST relevant to the amount of funding the Applicant is seeking. Please note if an individual is not registered for GST, or an organisation is a Government-Related Entity, value will be GST exclusive)

ITA 1213-02 of 34

Funding period12 months (1 July 2013-30 June 2014) up to $460,000 (GST exclusive)

12 months (1 July 2014-30 June 2015) up to $460,000 (GST exclusive)

12 months (1 July 2015-30 June 2016) up to $460,000 (GST exclusive)

GST exc GST* GST inc* GST exc GST* GST inc* GST exc GST* GST inc*

Funding itemStaffing costs (include FTE)

Main activities/ role of personnel

e.g. Administrative Assistant, Mr John Smith 1.0 FTE, HEO level 4

Organise committee meetings, develop agendas, take meeting notes, prepare meeting minutes, and follow up on actions arising.

$40,000 N/A N/A $44,000 N/A N/A $48,000 N/A N/A

<insert line item><insert line item><insert additional lines as required>Total staffing costsAdministrative costs GST exc GST* GST inc* GST exc GST* GST inc* GST exc GST* GST inc*Education and training:<insert line item><insert line item><insert additional lines as required>Office costs<insert line item><insert line item>

ITA 1213-02 of 34

<insert additional lines as required>IT support<insert line item><insert line item><insert additional lines as required>Travel<insert line item><insert line item><insert additional lines as required>Total Administrative costsAsset costs GST exc GST* GST inc* GST exc GST* GST inc* GST exc GST* GST inc*<insert line item><insert line item><insert additional lines as required>Total Asset costsTotal Group Costs^ $ $ $ $ $ $ $ $ $

* Please note, if an individual is not registered for GST, or an organisation is a Government Related Entity, value of all budget items will be GST exclusive^ Total Group Costs should not exceed $460,000 GST exclusive per financial year

ITA 1213-02 of 34

Value for MoneyPlease provide justification of costs in the budget table ensuring the budget requested and associated justification aligns with the key activities and outcomes specified in Assessment Criterion 2. (limit one page)

<Insert Value for Money justification>

ITA 1213-02 of 34

Monitoring and ReportingPlease note monitoring and reporting of progress against this grant will be in line with Cancer Australia’s Supporting cancer clinical trials in Australia Evaluation framework and performance criteria.

Section 3 - AcknowledgementsIf this Application for funding is successful, the National Cancer Cooperative Trials Group and the incorporated body through which the Funding Agreement will be administered (If applicable) acknowledges and agrees:

that a description of the project, the amount of the funding and name of the National Cancer Cooperative Trials Group and incorporated body may be:

included in the Agency’s reporting on the internet in line with the Commonwealth Grant Guidelines and Senate Orders;

used by Cancer Australia in media releases and other publications (such as Annual Reports); and/or

used to compile a consolidated report.

that it will be required to provide proof that it has sufficient insurance cover to conduct the proposed activities specified in this Application Form (see Part A, Clause 10); and

that the funding will be provided in accordance with the terms of Cancer Australia’s Standard Funding Agreement and the National Cancer Cooperative Trials Group and incorporated body agree to abide by the terms of that Agreement.

[Indicate whether the National Cancer Cooperative Trials Group makes the above acknowledgements] YES / NO

If NO, please explain why the National Cancer Cooperative Trials Group has not made the above acknowledgements.

..........................................................................................................................

..............................

..........................................................................................................................

..............................

..........................................................................................................................

..............................

[Indicate whether the incorporated body (if applicable) makes the above acknowledgements] YES / NO

If NO, please explain why the incorporated body (if applicable) has not made the above acknowledgements.

ITA 1213-02 of 34

..........................................................................................................................

..............................

..........................................................................................................................

..............................

..........................................................................................................................

..............................

ITA 1213-02 of 34

Section 4 - Declaration

This Declaration must be signed by an authorised representative of the Applicant (or, if this Application is a joint Application, an authorised representative of the Lead Organisation). The authorised representative should be a person who is legally empowered to enter into contracts and commitments on behalf of the Applicant / Lead Organisation.

An Application which does not provide all required information or which contains false or misleading information may be excluded from consideration.

I hereby apply for a grant under the Support for Cancer Clinical Trials program of

$ <insert value> GST inclusive/exclusive for <insert National Cancer Cooperative Trials Group name>.

I certify that the information given in this Application is complete and correct.

I declare that the Applicant is not listed as a terrorist under section 15 of the Charter of the United Nations Act 1945.1

Signature:(Chair of National Cancer Cooperative Trials Group)

Name (BLOCK LETTERS):

Position in Applicant:

Date:

Signature:(representative of the incorporated body through which the Funding Agreement will be administered)

Name (BLOCK LETTERS):

Position in Applicant:

Date:1

ITA 1213-02 of 34

Part E – Frequently asked questions

In this Part we have included some sample answers to frequently asked questions.

Will late Applications be accepted?

Cancer Australia will only accept your Application if it is late as a direct result of mishandling by Cancer Australia.

In all other circumstances, in the interests of fairness, Cancer Australia reserves the right not to accept late Applications. In considering whether it would be fair to accept a late Application, Cancer Australia will take into account the degree of lateness, whether the cause of the lateness was beyond the Applicant's control and such other facts as it considers relevant. Cancer Australia may also ask the Applicant to provide evidence to support its claims regarding the reasons for late submittal.

If the Applicant considers that their Application will be late they should notify the Contact Officer prior to the Closing Time, advising of the circumstances for the lateness. The Chair of the assessment committee will take these reasons into consideration when deciding whether or not to accept the late Application.

When will my Group find out if my Application has been successful?

It is anticipated that Applicants will be notified of the outcome by 31 May 2013.

Why does the Funding Agreement need to be administered through an incorporated body? For legal and accountability reasons, only incorporated bodies can

enter into a Funding Agreement with the Australian Government. It is not necessary for the National Cancer Collaborative Trials Group to become a company limited by guarantee or a separately incorporated body. The Group can administer their Funding Agreement through an incorporated body who can receive funding payments from Cancer Australia and make these available to the National Cancer Collaborative Trials Group.

If the National Cancer Cooperative Trials Group is not an incorporated body the Group must identify an incorporated body which is able to enter into the Funding Agreement. The incorporated body will, if your Application is successful, sign the Funding Agreement, receive the funding and assume legal responsibility for performing the Funding Agreement.

ITA 1213-02 of 34

Are there any GST or income tax-related issues involved in receiving funding?

Yes. Clause 4 of the Standard Funding Agreement outlines the taxes (including GST), duties and government charges for which successful funding Applicants will be responsible.

We recommend that you seek independent advice regarding the income tax implications of receiving funding.

When will my Group receive the funding?

If your Application for funding is successful, an initial payment may be made after the Funding Agreement has been signed by the nominated incorporated body and by Cancer Australia. All other payments of the funding may be based on deliverables (i.e. progress reports) as set out in the Funding Agreement.

Who should I contact if I need more information?

If you have any other questions or you need more information, you can contact the Contact Officer identified on the cover page of this Invitation to Apply for Funding.

Please ensure that you allow sufficient time for the Contact Officer to answer your query and for your organisation to complete its Application before the closing date. Queries should be received up to and no later than five business days before the closing date.

Will my Group have to spend the funding by a particular date? Yes. All funding must be expended by the Project Period end date

specified in the Funding Agreement. For three-year Funding Agreements funding must be expended by 30 June 2016.

Can my Group be offered less funding than it asked for? Yes. The Assessment Committee will review the parameters for

funding, budget, and value for money. The amount of funding offered will be based on demonstration of value for money and available funding.

Funding approval is at the discretion of Cancer Australia’s Funding Approver. Cancer Australia reserves the right to negotiate the level of funding and timeframe of funding with each Applicant.

Can costs associated with conducting specific cancer clinical trials be included in this grant application?

No. It is expected that National Cancer Cooperative Trials Groups will seek funding for the conduct and management of clinical trials from competitive grant sources.

ITA 1213-02 of 34

canceraustralia.gov.au€¦ · web viewinvitation to apply for funding . support for cancer...

Documents